Abstract: 3-O-?-D-Glucopyranosyl-4-methylergost-7-en-3-ol or a composition containing 0.001% by mass or more of the aforementioned compound, which is an extract of a plant of the family Liliaceae containing the compound or a fraction thereof, is used as an active ingredient of a hyperglycemia improving agent.

Abstract: A compound having a hyperglycemia improving effect and a hemoglobin A1c lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.

Abstract: A compound having a hyperglycemia improving effect and a hemoglobin A1c lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.

Abstract: A compound having a hyperglycemia improving effect and a hemoglobin A1c lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.

Abstract: A compound having a cyclolanostane skeleton such as 9,19-cyclolanostan-3-ol and 24-methylene-9,19-cyclolanostan-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.

Abstract: 3-O-?-D-Glucopyranosyl-4-methylergost-7-en-3-ol or a composition containing 0.001% by mass or more of the aforementioned compound, which is an extract of a plant of the family Liliaceae containing the compound or a fraction thereof, is used as an active ingredient of a hyperglycemia improving agent.

Abstract: 3-O-?-D-Glucopyranosyl-4-methylergost-7-en-3-ol or a composition containing 0.001% by mass or more of the aforementioned compound, which is an extract of a plant of the family Liliaceae containing the compound or a fraction thereof, is used as an active ingredient of a hyperglycemia improving agent.

Abstract: 3-O-?-D-Glucopyranosyl-4-methylergost-7-en-3-ol or a composition containing 0.001% by mass or more of the aforementioned compound, which is an extract of a plant of the family Liliaceae containing the compound or a fraction thereof, is used as an active ingredient of a hyperglycemia improving agent.

Abstract: A compound having a cyclolanostane skeleton such as 9,19-cyclolanostan-3-ol and 24-methylene-9,19-cyclolanostan-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.

Abstract: Aplasia of the corpus callosum or aspermatogenesis is diagnosed by investigating existence or expression of the BT-IgSF gene with use of a primer for PCR or probe for hybridization comprising a DNA coding for a novel cell adhesion molecule (BT-IgSF) defined in the following (A) or (B) or a partial sequence thereof: (A) a protein comprising the amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2; (B) a protein comprising an amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2 including substitution, deletion, insertion or addition of one or several amino acids and having a function as a cell adhesion molecule.

Abstract: A compound having a hyperglycemia improving effect and a hemoglobin Alc lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.

Abstract: Whey protein is hydrolyzed with hydrolase so that a rate of hydrolysis is preferably 20 to 30%. A fraction, which has molecular weights above 10,000 daltons, is removed from a resultant hydrolysate by means of an ultrafiltration method to obtain a whey protein hydrolysate which is used as an active ingredient of an interleukin-18 inducer.

Abstract: Aplasia of the corpus callosum or aspermatogenesis is diagnosed by investigating existence or expression of the BT-IgSF gene with use of a primer for PCR or probe for hybridization comprising a DNA coding for a novel cell adhesion molecule (BT-IgSF) defined in the following (A) or (B) or a partial sequence thereof: (A) a protein comprising the amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2; (B) a protein comprising an amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2 including substitution, deletion, insertion or addition of one or several amino acids and having a function as a cell adhesion molecule.

Abstract: Aplasia of the corpus callosum or aspermatogenesis is diagnosed by investigating existence or expression of the BT-IgSF gene with use of a primer for PCR or probe for hybridization comprising a DNA coding for a novel cell adhesion molecule (BT-IgSF) defined in the following (A) or (B) or a partial sequence thereof: (A) a protein comprising the amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2; (B) a protein comprising an amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2 including substitution, deletion, insertion or addition of one or several amino acids and having a function as a cell adhesion molecule.

Abstract: A protein hydrolysate comprising at least two types of peptides, characterized in that the rate of hydrolysis of protein is from 30 to 45%, the number average molecular weight is 300 or less, and the ratio of a weight average molecular weight to the number average molecular weight is greater than 1 and 2 or less, has excellent emulsifiability, and antigenicity thereof is low enough to be used for people who has predisposition to allergic diseases. This protein hydrolysate is obtained by hydrolysis of a protein starting material to a rate of hydrolysis in the range of 30 to 45%, and then bringing it into contact simultaneously or separately with two types of porous synthetic adsorbent respectively having an average pore radius of 2 to 8 nm and an average pore radius of 20 to 30 nm, the total surface area of the two porous synthetic adsorbents being in a range of 300 to 3000 m2 per 1 g (protein equivalent) of the obtained protein hydrolysate, and recovering the non-adsorbed component.

Abstract: A fat composition for oral or enteral administration which contains eicosapentaenoic acid and/or a derivative thereof, docosahexaenoic acid and/or a derivative thereof, and a C20 or higher monoenoic acid and/or a derivative thereof and functions to diminish hexacosanoic acid; and a hexacosanoic acid depressant which comprises as active ingredients eicosapentaenoic acid and/or a derivative thereof, docosahexaenoic acid and/or a derivative thereof, and a C20 or higher monoenoic acid and/or a derivative thereof. They can be prepared by extraction from a fish oil or the like, purification, blending, etc. Based on the function of diminishing hexacosanoic acid, the composition and the depressant produce an aging-inhibitory effect on cell membranes, which is effective in the prevention and treatment of lifestyle-related diseases.

Abstract: The present invention provides antiulcer agents which can be orally administered while producing few side effects. These antiulcer agents contain &agr;-lactalbumin as an active ingredient, preferably in an amount of at least 0.5 mg/g.

Abstract: Whey protein is hydrolyzed with hydrolase so that a rate of hydrolysis is preferably 20 to 30%. A fraction, which has molecular weights above 10,000 daltons, is removed from a resultant hydrolysate by means of an ultrafiltration method to obtain a whey protein hydrolysate which is used as an active ingredient of an interleukin-18 inducer.

Abstract: A fat composition for oral or enteral administration which contains eicosapentaenoic acid and/or a derivative thereof, docosahexaenoic acid and/or a derivative thereof, and a C20 or higher monoenoic acid and/or a derivative thereof and functions to diminish hexacosanoic acid; and a hexacosanoic acid depressant which comprises as active ingredients eicosapentaenoic acid and/or a derivative thereof, docosahexaenoic acid and/or a derivative thereof, and a C20 or higher monoenoic acid and/or a derivative thereof. They can be prepared by extraction from a fish oil or the like, purification, blending, etc. Based on the function of diminishing hexacosanoic acid, the composition and the depressant produce an aging-inhibitory effect on cell membranes, which is effective in the prevention and treatment of lifestyle-related diseases.

Abstract: The present invention relates to an interferon therapeutic effect enhancer that contains lactoferrin as its active ingredient; the use of lactoferrin for the production of an interferon therapeutic effect enhancer; a pharmaceutical composition having interferon and lactoferrin as its active ingredients; and, a disease treatment method that includes administration of said pharmaceutical composition, said interferon therapeutic effect enhancer and said pharmaceutical composition being able to improve the therapeutic effects of interferon against various diseases without the occurrence of adverse side effects.